Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
To the Editor: Dr Corey and colleagues1 reported that a recombinant glycoprotein vaccine
failed to prevent genital herpes simplex virus 2 (HSV-2) infection. The study
evaluated asymptomatic and symptomatic infections and symptomatic recurrences.
None of these outcomes were modified by vaccine despite neutralizing and antibody
titers that exceeded those produced during naturally acquired HSV-2 infection.
The authors suggest that more information is needed about cellular and mucosal
immune responses to HSV-2 infection before "we can attempt to identify laboratory-based
correlates of immune protection." While more information would be helpful,
the authors failed to consider currently available information that is relevant
to the vaccine failure.
Friedman HM. Immunologic Strategies for Herpes Vaccination. JAMA. 2000;283(6):746. doi:10.1001/jama.283.6.741